BofA Downgrades Arm to Neutral Amid Revenue Slowdown
BofA cuts Arm to Neutral with $120 target due to royalty slowdown, SoftBank reliance, and weaker smartphone sales in 2026.
Already have an account? Sign in.
BofA cuts Arm to Neutral with $120 target due to royalty slowdown, SoftBank reliance, and weaker smartphone sales in 2026.
FDA plans to restrict non-approved compounded GLP-1 drugs sold by Hims & Hers and compounding pharmacies, citing safety concerns and misleading marketing practices.
DraftKings (DKNG) partners with Crypto.com to expand prediction markets, adding player-specific sports contracts and new categories including politics and entertainment.
Analysts say Pfizer listing Chantix on TrumpRx may support Achieve Life Sciences and boost confidence in cytisinicline’s approval prospects.